Tenax Therapeutics, Inc. downgraded to Hold ahead of Aug 2026 phase 3 TNX-103 data in PH-HFpEF; weigh 6MWD odds, downside, ...
Seer is Delivering Clear Progress Against its Strategic Plan and Maintaining Focus on Cost Discipline, Governance Rigor and Product Innovation ...
When it comes to tackling prostate cancer , nobody puts it better than Sir Chris Hoy - doing nothing is not an option.